Compare TXRH & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXRH | SNN |
|---|---|---|
| Founded | 1993 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Restaurants | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 12.3B |
| IPO Year | 2004 | 2002 |
| Metric | TXRH | SNN |
|---|---|---|
| Price | $182.31 | $29.76 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 28 | 6 |
| Target Price | ★ $207.04 | $32.32 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 11-05-2026 | 08-04-2026 |
| Dividend Yield | 1.64% | ★ 2.51% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.72 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.91 | $4.85 |
| Revenue Next Year | $9.51 | $5.25 |
| P/E Ratio | ★ $49.21 | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $153.83 | $26.30 |
| 52 Week High | $216.30 | $37.09 |
| Indicator | TXRH | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 65.08 | 58.55 |
| Support Level | $179.82 | $29.18 |
| Resistance Level | $188.33 | $30.52 |
| Average True Range (ATR) | 5.35 | 0.46 |
| MACD | 2.48 | 0.15 |
| Stochastic Oscillator | 89.37 | 59.95 |
Texas Roadhouse Inc is a restaurant company operating predominantly in the casual dining segment. The company manages its restaurant and franchising operations by concept and, as a result, has identified Texas Roadhouse, Bubba's 33, Jaggers, and retail initiatives as separate operating segments. In addition, it has identified Texas Roadhouse and Bubba's 33 as reportable segments. Maximum revenue for the company is generated from the Texas Roadhouse segment, which is a moderately priced, full-service, casual dining restaurant concept offering steaks, a selection of ribs, seafood, chicken, pork chops, pulled pork, vegetable plates, and an assortment of hamburgers, salads, and sandwiches. Geographically, the majority of the firm's restaurants are in the USA, with a few in foreign countries.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.